- Report
- April 2024
- 80 Pages
South Korea
From €1341EUR$1,500USD£1,169GBP
From €1341EUR$1,500USD£1,169GBP
- Report
- April 2024
- 80 Pages
United Kingdom
From €1341EUR$1,500USD£1,169GBP
- Report
- April 2024
- 80 Pages
United States
From €1341EUR$1,500USD£1,169GBP
- Report
- April 2024
- 100 Pages
Africa
From €1788EUR$2,000USD£1,558GBP
- Drug Pipelines
- July 2023
- 144 Pages
Global
From €13402EUR$14,995USD£11,681GBP
- Report
- October 2024
- 93 Pages
Global
From €3500EUR$4,195USD£3,157GBP
- Report
- July 2023
- 108 Pages
Global
From €3500EUR$4,195USD£3,157GBP
- Report
- October 2022
- 63 Pages
Global
From €1788EUR$2,000USD£1,558GBP
The PCSK9 Inhibitor market is a subset of the Cardiovascular Drugs market. PCSK9 Inhibitors are a class of drugs used to lower cholesterol levels in patients with cardiovascular disease. These drugs work by blocking the action of the PCSK9 enzyme, which is responsible for breaking down LDL cholesterol in the body. PCSK9 Inhibitors are typically prescribed in combination with other cholesterol-lowering medications, such as statins.
PCSK9 Inhibitors have been shown to be effective in reducing LDL cholesterol levels, and have been approved for use in the United States and Europe. However, due to their high cost, they are not widely used.
Companies in the PCSK9 Inhibitor market include Amgen, Sanofi, Regeneron, and Pfizer. Show Less Read more
